Cedazuridine is a small molecule inhibitor of cytidine deaminase that is used as a pharmacoenhancer of decitabine to increase oral bioavailability of this DNA methylase inhibitor treatment of myelodysplastic syndromes. The combination of oral decitabine and cedazuridine is associated with a low rate of minor serum enzyme elevations during therapy that is usually attributed to decitabine. The oral combination has not been linked to cases of clinically apparent liver injury.
塞扎胞苷是一种胞苷脱氨酶小分子抑制剂，用作地西他滨的药物增强剂，以提高这种用于治疗骨髓增生异常综合征的DNA甲基化酶抑制剂的口服生物利用度。口服地西他滨和塞扎胞苷的联合用药在治疗期间血清酶轻度升高的发生率较低，这通常归因于地西他滨。口服联合用药尚未与临床明显肝损伤病例相关联。
